Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2025-12-26 @ 1:41 AM
Study NCT ID:
NCT03583333
Status:
COMPLETED
Last Update Posted:
2025-01-29
First Post:
2018-06-28
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-09-18
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-07-12
Completion Date Type:
ACTUAL
First Submit Date:
2018-06-28
First Submit QC Date:
None
Study First Post Date:
2018-07-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-05-26
Results First Submit QC Date:
None
Results First Post Date:
2023-06-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-15
Last Update Post Date:
2025-01-29
Last Update Post Date Type:
ACTUAL